Oncology
Synovial Sarcoma
26
Pipeline Programs↗
4
Active Trials↗
12
Companies Involved↗
Synovial Sarcoma is an emerging landscape with 26 programs across 12 companies. The most active players are Eli Lilly, C4 Therapeutics, Inc., Foghorn Therapeutics Inc.. 1 therapy is approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 112
Phase 27
Phase 35
Approved1
Analysis
Modality Breakdown
26programs
Small molecule1558%
Monoclonal antibody415%
Cell therapy415%
Radiopharmaceutical28%
Protein / enzyme14%
Modality classified for 100% of 28 pipeline programs.
Analysis
Trial Status
20
clinical trials
Terminated8 · 40%
Completed5 · 25%
Withdrawn3 · 15%
Active, not recruiting2 · 10%
Not yet recruiting1 · 5%
Recruiting1 · 5%
Clinical Trials
Trial Activity
20 trials
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Recruiting·—·Phase 3·NCT07174427·5 enrolled
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00052754·48 enrolled
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Completed·—·Phase 1/2·NCT03250325·8 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)